Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 6/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18159335 | 0.90 | IDO1 (0.47) | IDO1PKMGPR119HRH3NAMPT | |
| SCHEMBL18148436 | 0.86 | IDO1 (0.43) | IDO1TRPM8TRPV1 | |
| SCHEMBL25342059 | 0.86 | IDO1 (0.47) | IDO1PKMGPR119HRH3TRPM8 | |
| SCHEMBL25339942 | 0.85 | IDO1 (0.45) | IDO1PKMGPR119HRH3TRPM8 | |
| SCHEMBL25340767 | 0.85 | IDO1 (0.45) | IDO1PKMGPR119HRH3TRPM8 | |
| SCHEMBL1690860 | 0.85 | IDO1 (0.47) | IDO1GPR119HRH3TRPM8TRPV1 | |
| SCHEMBL31236009 | 0.85 | IDO1 (0.54) | IDO1GPR119HRH3 | |
| SCHEMBL12482111 | 0.83 | IDO1 (0.58) | IDO1GPR119HRH3TRPM8TRPV1 | |
| SCHEMBL20096619 | 0.82 | IDO1 (0.56) | IDO1PKMGPR119HRH3 | |
| SCHEMBL11489958 | 0.82 | IDO1 (0.38) | IDO1TRPM8TRPV1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9637453-B2 | 3-spirocyclic-6-hydroxamic acid tetralins as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637453-B2 | 3-spirocyclic-6-hydroxamic acid tetralins as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9637453-B2 | 3-spirocyclic-6-hydroxamic acid tetralins as HDAC inhibitors | FORMA THERAPEUTICS, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| WO-2016168598-A1 | 3-SPIROCYCLIC-6-HYDROXAMIC ACID TETRALINS AS HDAC INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016168598-A1 | 3-SPIROCYCLIC-6-HYDROXAMIC ACID TETRALINS AS HDAC INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| US-20160304456-A1 | 3-SPIROCYCLIC-6-HYDROXAMIC ACID TETRALINS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160304456-A1 | 3-SPIROCYCLIC-6-HYDROXAMIC ACID TETRALINS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160304456-A1 | 3-SPIROCYCLIC-6-HYDROXAMIC ACID TETRALINS AS HDAC INHIBITORS | VALO HEALTH, INC. | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304456-A1 | 3-SPIROCYCLIC-6-HYDROXAMIC ACID TETRALINS AS HDAC INHIBITORS | HDAC1, HDAC11, HDAC6 | IDO1 811/4885PKM 2057/4885GPR119 1203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.